Bio-Technopark
In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On the former site of the Schweizerische Wagons- und Aufzügefabrik AG and on neighboring sites, 100,000 m2 of laboratory, production and office space is now leased to around 60 companies and organizations, and 80 academic research groups. Video
Leasing
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with partly shared infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
Services
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
News
Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. The funds will support continued clinical and development activities for V-212, Virometix’s lead serotype-independent pneumococcal vaccine candidate, currently in Phase I clinical evaluation. Proceeds from the financing...
InSphero Expands 3D Cell Model Leadership with Acquisition of DOPPL SA and Sun Bioscience Gri3D® Technology
InSphero AG, the global market leader in 3D cell-based assays and organ-on-chip systems signed the definitive agreement to acquire DOPPL SA, a Lausanne-based innovator in the organoid space, including the Sun Bioscience Gri3D® technology. The acquisition strengthens InSphero’s position as the most comprehensive provider of advanced 3D in vitro models, combining scalable spheroid and organoid technologies with...